Mantle Cell Lymphoma Articles

CAR T-Cell Therapy Explored in Mantle Cell Lymphoma
The CD19-targeted CAR T-cell product axicabtagene ciloleucel (axi-cel; Yescarta) is currently being investigated in patients with relapsed/refractory MCL in the ongoing ZUMA-2 trial. 
Ibrutinib/Buparlisib Reaches Response in Half of NHL Cohort
Combining the BTK inhibitor ibrutinib (Imbruvica) with the PI3K inhibitor buparlisib induced an objective response in 18 of 37 patients with relapsed/refractory non-Hodgkin lymphoma.
CDK4/6 Inhibition Shows Early Promise in Mantle Cell Lymphoma
Selina Chen-Kiang, PhD, details the research being conducted with CDK4/6 inhibitors in mantle cell lymphoma.
CAR T-Cell Therapy Starts to Enter MCL Space
Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma. 
Taking the Next Step in MCL: Novel Combos and Immunotherapy Under Study
Despite advancements in treatment strategies for mantle cell lymphoma, patients experience diminishing responses from sequential lines of therapy as their disease progresses, sharpening the focus on developing new agents and combinations.
The combination of venetoclax and ibrutinib induced a 16-week complete response rate of 42% per CT imaging in patients with previously untreated or relapsed/refractory mantle cell lymphoma.
MCL Leader Discusses Optimal Disease Management
Andre Goy, MD, discusses the evolution of MCL treatment, specifically the integration of new agents in both the frontline and relapsed/refractory settings, and the importance of MRD status and maintenance therapies.
Goy Lends Insight on Acalabrutinib and Ibrutinib in MCL
Andre Goy, MD, discusses the excitement surrounding acalabrutinib, as well as emerging ibrutinib combination strategies for the treatment of patients with mantle cell lymphoma.
Flinn Sheds Light on Advances in MCL and Other Lymphomas
Ian W. Flinn, MD, PhD, discusses the impact of CAR T-cell therapy on the field of lymphoma and highlighted emerging options for the treatment of patients with MCL.
Ibrutinib Continues to Demonstrate Effectiveness in MCL
Brad S. Kahl, MD, discusses the latest data for ibrutinib and highlights emerging treatments in mantle cell lymphoma. 
Publication Bottom Border
Border Publication